Navigation Links
Pharmexa A/S (DK) - Long lasting immune response and survival to,RAS vaccine

Summary: Follow-up RAS data presented at ASCO

HORSOLM, Denmark, June 4, 2007-Professor Trond Buanes today gave a presentation titled "RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival" at ASCO's (American Society of Clinical Oncology) annual cancer meeting.

A follow-up study of 23 resected pancreatic cancer patients immunized in the period from 1995 to 1998 with two different peptide vaccines targeting the RAS mutation found in most instances of pancreatic cancer indicates that a long lasting immune response is possible following immunization with a peptide vaccine. Five patients that showed an immune response to the vaccine were still alive in 2006, i.e. up to 10 years after the operation. Further analysis showed that the immune system in three of these patients still remembered the RAS vaccination.

The RAS vaccines are owned by Pharmexa. In addition, Pharmexa owns a number of other proprietary cancer peptide vaccines, including GV1001 which is in phase III clinical trials.

Hørsholm, June 4, 2007

Jakob Schmidt Chief Executive Officer

Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepat itis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.

http://hugin.info/131680/R/1130841/211128.pdf


'"/>




Related medicine technology :

1. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
2. Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex
3. Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
8. Apollo develops needle-free topical vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... 2017   PDI , a leader in infection ... an educational session focused on the role of chlorhexidine ... at the 2017 Annual Scientific Meeting of the Association ... at the Phoenix Convention Center ... 16-19, will also feature PDI,s Prevantics® Device Swab ...
(Date:9/5/2017)... 5, 2017  Xyntek Inc. has announced another milestone in their continued growth ... to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite ... Xyntek's ... ...
(Date:9/1/2017)... Sept. 1, 2017 Michael Penna , ... , highlights opportunities for growth in his response to ... Marlin Equity is seeking a buyer for eMDs. Penna,s ... 22-year-old healthcare solutions Value Added Reseller and national leader ... "As the healthcare market continues to ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “Monique”: is the story of Monique, ... the creation of published author, Colleen Crispi, has owned four beauty salons and written ... involved in real estate and cooking. , “The doctor’s office was only three ...
(Date:9/19/2017)... ... 2017 , ... Only a few physicians were selected to receive the prestigious ... Clevens, MD, FACS . The founder and medical director of Clevens Face and ... at Yale, Harvard and the University of Michigan. He has served patients throughout Central ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... St. Vincent’s Infusion Services called, “PAPA Healthcare helps fill gaps, provide essential insights, ... enhanced service delivery and operations by leveraging PAPA Healthcare’s post-acute productivity and analytics ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... Environmental Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor ... USAID’s Innovation to Action Award. , The Innovation to Action Award, a ...
(Date:9/19/2017)... ... 19, 2017 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... national Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted ...
Breaking Medicine News(10 mins):